Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.
JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.15, 2021 (Peer-Reviewed Journal)
Article / Abstract
JOURNAL OF CLINICAL ONCOLOGY
Science Citation Index Expanded, Scopus, PASCAL, CAB Abstracts, CINAHL, EMBASE, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database